GeoVax Labs (NASDAQ:GOVX) Releases Quarterly Earnings Results, Misses Estimates By $1.02 EPS

GeoVax Labs (NASDAQ:GOVX) announced its quarterly earnings results on Thursday. The company reported ($2.62) EPS for the quarter, missing the consensus estimate of ($1.60) by ($1.02), FiscalAI reports.

GeoVax Labs Trading Down 2.4%

NASDAQ GOVX opened at $1.23 on Friday. The company has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $4.67. The company has a market cap of $3.55 million, a P/E ratio of -0.03 and a beta of 3.36. GeoVax Labs has a 1 year low of $0.96 and a 1 year high of $34.75.

Institutional Trading of GeoVax Labs

Several large investors have recently modified their holdings of GOVX. Jane Street Group LLC bought a new stake in shares of GeoVax Labs during the 1st quarter worth $27,000. HRT Financial LP bought a new stake in shares of GeoVax Labs during the 4th quarter worth $31,000. Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs during the 4th quarter worth $104,000. Finally, Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter worth $253,000. 6.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on GOVX. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of GeoVax Labs to a “strong sell” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $150.00.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.